Search Results - "Avalos, B."

Reliability of a handball specific strength test battery and the association with sprint and throwing performance in young handball players by MORENAS-AGUILAR, María D., RODRIGUEZ-PEREA, Angela, CHIROSA-RIOS, Luis J., JEREZ-MAYORGA, Daniel, VILA, Helena, AVALOS SOLITARIO, Aldo B., SOTO-GARCÍA, Diego

“…BACKGROUND: A greater motivation for coaches to be more involved in assessment could be the development of specific strength tests closer to specific handball…”
Get full text

Experimental design for the optimization of copper biosorption from aqueous solution by Aspergillus terreus by Cerino-Córdova, F.J., García-León, A.M., Soto-Regalado, E., Sánchez-González, M.N., Lozano-Ramírez, T., García-Avalos, B.C., Loredo-Medrano, J.A.

“…An experimental design methodology was applied to study the effects of temperature, pH, biomass dose, and stirring speed on copper removal from aqueous…”
Get full text

Hematopoietic cell transplantation in MDS: undervalued and underutilized by Grunwald, M R, Avalos, B R, Copelan, E A

Get full text

Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors by Nash, Richard A., Antin, Joseph H., Karanes, Chatchada, Fay, Joseph W., Avalos, Belinda R., Yeager, Andrew M., Przepiorka, Donna, Davies, Stella, Petersen, Finn B., Bartels, Pamela, Buell, Donald, Fitzsimmons, William, Anasetti, Claudio, Storb, Rainer, Ratanatharathorn, Voravit

“…After the transplantation of unmodified marrow from human leukocyte antigen-matched unrelated donors receiving cyclosporine (CSP) and methotrexate (MTX), the…”
Get full text

Etoposide plus G-CSF priming compared with G-CSF alone in patients with lymphoma improves mobilization without an increased risk of secondary myelodysplasia and leukemia by Mahindra, A, Bolwell, B J, Rybicki, L, Elder, P, Kalaycio, M, Dean, R, Avalos, B, Sobecks, R, Tench, S, Andresen, S, Pohlman, B, Sweetenham, J, Devine, S, Copelan, E

“…The use of etoposide (VP-16) for stem cell mobilization has been reported as a significant risk factor for the development of therapy-related…”
Get full text

Use of the Trifunctional Cyclic Initiator, DEKTP, as the Radical Initiator in the Modification of Poly(propylene) in the Presence of Different Branching/Crosslinking Co-Agents by García, L., Morales, G., Avalos B, F., Acuña, P.

“…Homopolypropylene was modified in the molten state using a new cyclic multifunctional peroxide as the initiator, the Diethyl Ketone Triperoxide (DEKTP), in the…”
Get full text

Granulocyte colony-stimulating factor receptor mutations in severe congenital neutropenia transforming to acute myelogenous leukemia confer resistance to apoptosis and enhance cell survival by Hunter, Melissa G., Avalos, Belinda R.

“…Patients with severe congenital neutropenia (SCN) are at increased risk for the development of acute myelogenous leukemia (AML). In the subset of patients with…”
Get full text

Molecular characterization and expression analysis of leucine-rich alpha 2-glycoprotein, a novel marker of granulocytic differentiation by O'Donnell, L C, Druhan, L J, Avalos, B R

“…Using data obtained from cDNA representational difference analysis to identify genes induced during neutrophilic differentiation of the 32D clone 3G (32Dcl3G)…”
Get full text

Cognitive Event-Related Potentials (P300) and Cognitive Impairment in Duchenne Muscular Dystrophy by Esquitin-Garduño, N., Escobar-Cedillo, R. E., Flores-Avalos, B. G., Escobar-Cedillo, G., Miranda-Duarte, A., López-Hernández, L. B., Orellana-Villazón, V. I., Coral-Vázquez, R. M., García, S., Gómez-Díaz, B.

“…Duchenne muscular dystrophy (DMD) is a progressing disorder characterized by muscle wasting and weakness due to the absence or alteration of the function of…”
Get full text

Busulfan levels are influenced by prior treatment and are associated with hepatic veno-occlusive disease and early mortality but not with delayed complications following marrow transplantation by COPELAN, E. A, BECHTEL, T. P, AVALOS, B. R, ELDER, P. J, EZZONE, S. A, SCHOLL, M. D, PENZA, S. L

“…Long-term outcome was analyzed in 28 patients transplanted between 1989 and 1992 following busulfan and cyclophosphamide and who had busulfan levels studied…”
Get full text

High-dose busulfan, cyclophosphamide, and etoposide does not improve outcome of allogeneic stem cell transplantation compared to BuCy2 in patients with acute myeloid leukemia by FARAG, S. S, BOLWELL, B. J, AVALOS, B. R, BYRD, J. C, COPELAN, E, ELDER, P. J, KALAYCIO, M, LIN, T, POHLMAN, B, PENZA, S, MARCUCCI, G, BLUM, W, SOBECKS, R

“…To reduce relapse following allogeneic transplantation for AML, intensification of high-dose busulfan/cyclophosphamide using additional agents has been…”
Get full text

Autotransplantation following busulfan, etoposide and cyclophosphamide in patients with non-Hodgkin's lymphoma by COPELAN, E. A, PENZA, S. L, EZZONE, S. A, O'DONNELL, L. C, TIGHE, M. B, RISLEY, G. L, YOUNG, D. C, BOLWELL, B. J, POHLMAN, B, AVALOS, B. R, GOORMASTIC, M, ANDRESEN, S. W, KALAYCIO, M, BECHTEL, T. P, SCHOLL, M. D, ELDER, P. J

“…The purpose of the study was to determine the toxicities and effectiveness of a novel preparative regimen of busulfan (Bu) 14 mg/kg, etoposide 50 or 60 mg/kg,…”
Get full text

Second autologous stem cell transplant for multiply relapsed Hodgkin's disease by LIN, T. S, AVALOS, B. R, PENZA, S. L, MARCUCCI, G, ELDER, P. J, COPELAN, E. A

“…Therapeutic options for patients with Hodgkin's disease who relapse after high-dose chemotherapy with autologous stem cell support are limited. Salvage…”
Get full text

Diffuse alveolar hemorrhage following gemtuzumab ozogamicin by Lin, T S, Penza, S L, Avalos, B R, Lucarelli, M R, Farag, S S, Byrd, J C, Copelan, E A

Get full text

Mobilization of peripheral-blood progenitor cells with high-dose etoposide and granulocyte colony-stimulating factor in patients with breast cancer, non-Hodgkin's lymphoma, and Hodgkin's disease by Copelan, E A, Ceselski, S K, Ezzone, S A, Lasky, L C, Penza, S L, Bechtel, T P, Klein, J L, Hehmeyer, D M, Scholl, M D, Marshall, D D, Elder, P J, Risley, G L, Avalos, B R

“…We analyzed the safety and effectiveness of high-dose etoposide (2 g/m2) followed by granulocyte colony-stimulating factor (G-CSF) as a peripheral-blood…”
Get more information

Human Granulocyte Colony-Stimulating Factor: Biologic Activities and Receptor Characterization on Hematopoietic Cells and Small Cell Lung Cancer Cell Lines by Avalos, Belinda R., Gasson, Judith C., Hedvat, Cyrus, Quan, Shirley G., Baldwin, Gayle C., Weisbart, Richard H., Williams, Robert E., Golde, David W., DiPersio, John F.

“…Human granulocyte colony-stimulating factor (G-CSF) is a regulatory glycoprotein that stimulates the production of neutrophilic granulocytes from committed…”
Get full text

Influence of Hydrodynamic Interactions on the Kinetics of Colloidal Particles' Adsorption by Wojtaszczyk, P., Avalos, J. B.

Get full text

Nonhematopoietic Tumor Cells Express Functional GM-CSF Receptors by Baldwin, Gayle Cocita, Gasson, Judith C., Kaufman, Susan E., Quan, Shirley G., Williams, Robert E., Avalos, Belinda R., Gazdar, Adi F., Golde, David W., DiPersio, John F.

“…Human granulocyte-macrophage colony-stimulating factor (GM-CSF) stimulates the colony growth of myeloid progenitors in semisolid media, and enhances the…”
Get full text

Analysis of prognostic factors for allogeneic marrow transplantation following busulfan and cyclophosphamide in myelodysplastic syndrome and after leukemic transformation by COPELAN, E. A, PENZA, S. L, ELDER, P. J, EZZONE, S. A, SCHOLL, M. D, BECHTEL, T. P, BELT, P. S, AVALOS, B. R

“…Prognostic factors in 42 patients aged 11 to 62 (median 46) years, with myelodysplastic syndrome (MDS) or after leukemic transformation, who underwent…”
Get full text

HLA-B44-directed cytotoxic T cells associated with acute graft-versus-host disease following unrelated bone marrow transplantation by Keever, C A, Leong, N, Cunningham, I, Copelan, E A, Avalos, B R, Klein, J, Kapoor, N, Adams, P W, Orosz, C G, Tutschka, P J

“…We describe the recipient of a marrow graft from an HLA-serologically identical unrelated donor from whom highly potent host-reactive CTL of donor origin were…”
Get more information